CMP Development LLC v. MSN Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: CMP Development LLC (Delaware)
  • Defendant: MSN Pharmaceuticals, Inc. (Delaware) and MSN Laboratories Pvt. Ltd. (India)
  • Plaintiff's Counsel: McCarter & English, LLP; Merchant & Gould, P.C.
• Case Identification: 2:26-cv-02653, D.N.J., 03/16/2026
• Venue Allegations: Venue is alleged based on Defendant MSN Pharmaceuticals, Inc. having its principal place of business in Piscataway, New Jersey, and both defendants regularly transacting business in the district. The complaint also notes that the defendants have previously invoked the jurisdiction of this court in other patent matters.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's TADLIQ® oral suspension constitutes an act of infringement of four U.S. patents related to liquid oral formulations of tadalafil.
• Technical Context: The technology concerns pharmaceutical formulations designed to deliver tadalafil, a poorly water-soluble drug, in a ready-to-use liquid oral suspension, primarily for patients with difficulty swallowing, such as those with pulmonary arterial hypertension.
• Key Procedural History: The litigation was initiated by this complaint following Plaintiff's receipt of Defendants' notice letter, which contained a Paragraph IV certification alleging that the patents-in-suit are invalid, unenforceable, or would not be infringed by the proposed generic product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,382,917 - "Liquid Oral Formulations for Tadalafil," issued July 12, 2022

The Invention Explained

• Problem Addressed: The patent's background section describes the technical challenge that tadalafil has very low water solubility (about 2 µg/mL) and bioavailability, making it difficult to formulate as a stable and effective liquid oral medication U.S. Patent No. 11,382,917, col. 7:1-10 It also notes that existing powder-for-reconstitution formulations are inconvenient and difficult for patients or caregivers to prepare correctly U.S. Patent No. 11,382,917, col. 8:50-col. 9:24
• The Patented Solution: The invention provides a ready-to-use liquid oral suspension of tadalafil that overcomes these challenges. The solution involves combining tadalafil with a specific combination of pharmaceutical excipients, including a vehicle (water), a wetting agent, a buffering agent to control pH, and an anti-foaming agent, to create a stable, palatable, and easily dispersible suspension U.S. Patent No. 11,382,917, abstract U.S. Patent No. 11,382,917, col. 13:12-30
• Technical Importance: This approach provides a ready-to-use liquid dosage form for a poorly soluble drug, which improves patient compliance and dosing accuracy for populations that cannot swallow solid tablets, such as pediatric and geriatric patients U.S. Patent No. 11,382,917, col. 9:36-41

Key Claims at a Glance

• The complaint alleges infringement of one or more claims without specifying which Compl. ¶49 Independent claim 1 is representative.
• Independent Claim 1 Elements:
  • A liquid oral pharmaceutical composition, comprising:
  • about 4 mg/mL tadalafil or a pharmaceutically acceptable salt thereof;
  • a pharmaceutically acceptable excipient; and
  • a vehicle comprising water;
  • wherein the pharmaceutical composition has a pH of from about 4 to about 8; and
  • wherein the pharmaceutically acceptable excipient comprises an anti-foaming agent comprising a simethicone, a simethicone emulsion, an organic phosphate, a paraffin oil, a stearate, a glycol, or a combination thereof, in an amount of from about 0.1 mg/mL to about 100 mg/mL.
• The complaint does not explicitly reserve the right to assert dependent claims but alleges infringement of "one or more claims" Compl. ¶49

U.S. Patent No. 11,666,576 - "Liquid Oral Formulations for Tadalafil," issued June 6, 2023

The Invention Explained

• Problem Addressed: Similar to the '917 Patent, the '576 Patent addresses the poor solubility and bioavailability of tadalafil, which complicates the development of liquid dosage forms U.S. Patent No. 11,666,576, col. 7:5-10 The patent highlights the need for a stable, effective, and palatable oral liquid formulation to overcome the challenges associated with solid tablets and powders for reconstitution U.S. Patent No. 11,666,576, col. 7:51-60
• The Patented Solution: The invention is a ready-to-use liquid oral composition that combines tadalafil with a vehicle (water) and a specific set of excipients. The claimed solution requires a wetting agent (e.g., glycerin) within a specific concentration range, along with a preservative, sweetener, and flavorant, to ensure the drug is properly dispersed and the final product is palatable and stable U.S. Patent No. 11,666,576, abstract U.S. Patent No. 11,666,576, col. 13:1-24
• Technical Importance: This formulation provides a ready-to-use liquid dosage form of tadalafil that improves patient adherence by offering consistent dosing, better taste, and eliminating the need for complex preparation by the patient or caregiver U.S. Patent No. 11,666,576, col. 9:1-8

Key Claims at a Glance

• The complaint alleges infringement of one or more claims without specification Compl. ¶57 Independent claim 1 is representative.
• Independent Claim 1 Elements:
  • A liquid oral pharmaceutical composition comprising:
  • about 4 mg/mL tadalafil or a pharmaceutically acceptable salt thereof;
  • a pharmaceutically acceptable excipient comprising a wetting agent comprising ethanol, glycerin, propylene glycol, or a combination thereof in an amount of about 100 mg/mL to about 1000 mg/mL; and
  • a vehicle comprising water;
  • wherein the pharmaceutical composition has a pH of from about 4 to about 8;
  • wherein the pharmaceutically acceptable excipient further comprises a preservative, a sweetener, a flavorant, or a combination thereof; and
  • wherein the preservative is present in an amount of from about 0.1 mg/mL to about 100 mg/mL, the sweetener is present in an amount of: from about 0.1 mg/mL to about 50 mg/mL, and the flavorant is present in an amount of from about 0.1 mg/mL to about 50 mg/mL.
• The complaint alleges infringement of "one or more claims" Compl. ¶57

Multi-Patent Capsule: U.S. Patent No. 11,975,006 - "Liquid Oral Formulations for Tadalafil," issued May 7, 2024

• Technology Synopsis: The '006 Patent, like the others in its family, is directed to stable, ready-to-use liquid oral formulations of tadalafil. It addresses the technical challenges of tadalafil's low water solubility by claiming a specific composition of excipients, including a required pH of about 5 and a wetting agent within a defined concentration range, to create an effective and patient-friendly suspension.
• Asserted Claims: The complaint alleges infringement of "one or more claims" of the '006 Patent Compl. ¶65 Independent claim 1 is a key claim.
• Accused Features: The complaint alleges that the MSN ANDA Product contains the same active ingredient (tadalafil) and, upon information and belief, includes an excipient or combination of excipients that performs substantially the same function as the "wetting agents" recited in the claims of the '006 Patent Compl. ¶64

Multi-Patent Capsule: U.S. Patent No. 12,186,322 - "Liquid Oral Formulations for Tadalafil," issued January 7, 2025

• Technology Synopsis: The '322 Patent continues the themes of the asserted patent family, describing a ready-to-use liquid oral composition of tadalafil. The claimed invention specifies a formulation with tadalafil particles of a certain size (d90 particulate size of from about 1 micron to about 200 microns) and a wetting agent to ensure stability and proper dispersion, addressing the difficulties of formulating the poorly soluble drug.
• Asserted Claims: The complaint alleges infringement of "one or more claims" of the '322 Patent Compl. ¶73 Independent claim 1 is a key claim.
• Accused Features: Infringement allegations for the '322 Patent are based on the MSN ANDA Product containing tadalafil and, upon information and belief, an excipient or combination thereof that performs substantially the same function as the "wetting agents" recited in the patent's claims Compl. ¶72

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is the "MSN ANDA Product," a generic drug for which Defendants have filed Abbreviated New Drug Application No. 221209 with the U.S. Food and Drug Administration Compl. ¶2 Compl. ¶3
• Functionality and Market Context:
  • The MSN ANDA Product is a generic version of Plaintiff's TADLIQ® product Compl. ¶3
  • It is described as a ready-to-use oral liquid suspension containing tadalafil as the active ingredient at a strength of 20 mg/5 mL Compl. ¶¶35-36 Compl. ¶38
  • The complaint alleges the product is bioequivalent to TADLIQ® and intended for the same use, which includes treatment of pulmonary arterial hypertension for patients who have difficulty swallowing tablets or capsules Compl. ¶9 Compl. ¶34 Compl. ¶39 Compl. ¶41
  • The product is intended for commercial manufacture, use, and sale in the United States upon FDA approval, before the expiration of the patents-in-suit Compl. ¶3 Compl. ¶13

IV. Analysis of Infringement Allegations

11,382,917 Patent Infringement Allegations

11,666,576 Patent Infringement Allegations

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Equivalency of Excipients: The complaint bases its infringement theory for key excipient limitations (e.g., "anti-foaming agent," "wetting agent") on "information and belief" that the accused product contains excipients performing a "substantially the same function" Compl. ¶48 Compl. ¶56 This suggests the core dispute may not be over literal infringement but will center on the doctrine of equivalents. The central question will be whether MSN's chosen excipients perform substantially the same function, in substantially the same way, to achieve substantially the same result as the claimed excipients.
  • Claim Scope: The case may raise questions about the scope of functional terms used in the claims. For example, the analysis will likely depend on how broadly terms like "anti-foaming agent" and "wetting agent" are construed, and what structural or chemical properties are required to meet those definitions.

V. Key Claim Terms for Construction

• The Term: "anti-foaming agent" (from '917 Patent, claim 1)

  • Context and Importance: This term is central because the complaint's infringement theory appears to rely on an equivalent, rather than identical, excipient in the MSN product Compl. ¶48 The definition of this term will determine whether MSN's formulation falls within the literal scope of the claim or if an equivalents analysis is necessary.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claim uses the broad term "anti-foaming agent" and provides a Markush group of examples ("a simethicone, a simethicone emulsion, an organic phosphate, a paraffin oil, a stearate, a glycol, or a combination thereof"), suggesting the term is not limited to only those examples. The specification provides a non-limiting list of anti-foaming agents, including "simethicone, organic phosphates, alcohols, paraffin oils, stearates, glycols and the like" '917 Patent, col. 22:49-51
    • Evidence for a Narrower Interpretation: A defendant may argue that the term should be limited by the context of creating a stable tadalafil suspension. The specification's examples use a "30% Simethicone Emulsion" '917 Patent, Table 2, which could be used to argue that the term should be construed to cover agents with similar properties to simethicone in this specific application.

• The Term: "wetting agent" (from '576 Patent, claim 1)

  • Context and Importance: Similar to the term above, the definition of "wetting agent" is critical because infringement is alleged based on an excipient that performs a "substantially the same function" Compl. ¶56 The construction of this term, including its required concentration, will be a primary focus.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: Claim 1 of the '576 Patent defines the wetting agent with a Markush group ("ethanol, glycerin, propylene glycol, or a combination thereof"), but the specification provides a much longer, non-limiting list of examples, including various chlorides, poloxamers, and polysorbates '576 Patent, col. 18:27-38 This may support a construction that is not limited to the three examples in the claim.
    • Evidence for a Narrower Interpretation: The specification emphasizes that glycerin as a wetting agent was found to make the PDE V inhibitor "easily dispersible, without being solubilized, allowing for a stable suspension to be made" '576 Patent, col. 13:25-29 A defendant might argue that the term "wetting agent" should be limited to substances that achieve this specific function in the context of a tadalafil suspension, potentially narrowing the scope from the broader class of all chemical wetting agents.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Defendants will actively induce infringement by others (e.g., patients, healthcare providers) and contribute to infringement, as the MSN ANDA Product is alleged to have no substantial non-infringing uses Compl. ¶49 Compl. ¶51 Compl. ¶57 Compl. ¶59
• Willful Infringement: The complaint alleges that Defendants had "actual and constructive knowledge" of the patents-in-suit prior to submitting their ANDA and had "specific intent to infringe" when filing it Compl. ¶46 Compl. ¶50 Compl. ¶54 Compl. ¶58 This allegation is based on pre-suit knowledge stemming from the existence of the patents and the Paragraph IV certification process.

VII. Analyst's Conclusion: Key Questions for the Case

1. A central issue will be one of technical and functional equivalence: As the complaint's infringement allegations for key limitations rely on "information and belief" that Defendants' excipients perform a "substantially the same function," the case will likely depend heavily on the doctrine of equivalents. A key question will be whether the specific excipients in the MSN ANDA Product function in substantially the same way to achieve the same result as the claimed "anti-foaming agents" and "wetting agents" within the specific chemical environment of a tadalafil suspension.

2. The dispute will also turn on a question of definitional scope during claim construction: The outcome will be significantly influenced by how the court construes functional terms such as "anti-foaming agent" and "wetting agent." The core legal question is whether these terms will be given a broad, dictionary-like definition or be narrowed by the patent's specification to the specific context of creating a stable, ready-to-use tadalafil oral liquid.